Abstract：Objective To investigate the application effect of Ticagrelor in antiplatelet therapy after percutaneous coronary intervention(PCI)for acute myocardial infarction.Methods A total of 100 patients with acute myocardial infarction admitted to Xiangzhou District People′s Hospital of Xiangyang city from January 2019 to June 2020 were selected as the research objects,and were divided into observation group and control group according to random number table method,with 50 patients in each group.The observation group received Aspirin+Ticagrelor before and after PCI,and the control group received Aspirin+Clopidogrel before and after PCI.The platelet aggregation rate,liver function,the incidence of adverse reactions and the total incidence of adverse cardiovascular events in two groups were compared.Results There was no significant difference in platelet aggregation rate between the two groups before operation(P>0.05).The platelet aggregation rate of observation group at 2,24 h and 7 d after surgery were lower than those of control group,the differences were statistically significant(P<0.05).There was no significant difference in liver function between the two groups before surgery(P>0.05).The levels of glutamic-oxalacetic transaminase and serum creatinine in the observation group at 7 d after operation were higher than those before operation and those in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse cardiovascular events in observation group was lower than that in control group,the difference was statistically significant(P<0.05).Conclusion Ticagrelor has a significant effect on antiplatelet therapy after PCI in acute myocardial infarction with high safety and is worthy of clinical promotion.In summary,ticagrelor is effective in antiplatelet therapy after PCI for acute myocardial infarction,and it is worthy of clinical application.
京公网安备 11010502046607号